1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride monohydrate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride monohydrate
• 英文别名: 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;hydrate;hydrochloride
• 化学式: C₂₆H₂₇N₅O₂*ClH*H₂O
• 分子量: 496.009
• InChiKey: WOWCLTHDNADLPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.63
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  103
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride monohydrate 生成 盐酸维拉唑酮
  参考文献：
  名称：

  POLYMORPHIC FORMS OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE

  摘要：

  本发明涉及1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪盐酸盐的新晶体形态、1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪双盐酸盐的晶体形态以及非晶态1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪盐酸盐，特别适用于制备用于治疗或预防抑郁症、焦虑症、双相障碍、躁狂、痴呆、物质相关障碍、性功能障碍、进食障碍、肥胖症、纤维肌痛、睡眠障碍、精神障碍、脑梗塞、紧张，用于治疗高血压、脑部疾病、慢性疼痛、肢端肥大症、性腺功能减退症、继发性闭经、经前综合征以及不良产褥期泌乳的副作用疗法。

  公开号：

  US20170182037A1
• 作为产物：
  描述：

  维拉佐酮 在 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 生成 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride monohydrate
  参考文献：
  名称：

  POLYMORPHIC FORMS OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE

  摘要：

  本发明涉及1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪盐酸盐的新晶体形态、1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪双盐酸盐的晶体形态以及非晶态1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪盐酸盐，特别适用于制备用于治疗或预防抑郁症、焦虑症、双相障碍、躁狂、痴呆、物质相关障碍、性功能障碍、进食障碍、肥胖症、纤维肌痛、睡眠障碍、精神障碍、脑梗塞、紧张，用于治疗高血压、脑部疾病、慢性疼痛、肢端肥大症、性腺功能减退症、继发性闭经、经前综合征以及不良产褥期泌乳的副作用疗法。

  公开号：

  US20170182037A1

文献信息

• NOVEL POLYMORPHS OF VILAZODONE HYDROCHLORIDE
  申请人：ORCHID CHEMICALS & PHARMACEUTICALS LIMITED

  公开号：US20140303185A1

  公开（公告）日：2014-10-09

  The present invention relates to novel crystalline polymorphic forms of Vilazodone hydrochloride of formula (I). This present invention further provides the process for the preparation of novel polymorphic forms of Vilazodone hydrochloride.

  本发明涉及公式（I）的维拉唑酮盐酸盐的新晶态多态形式。本发明还提供了制备维拉唑酮盐酸盐新多态形式的方法。
• POLYMORPHIC FORMS OF 1-'4-(5-CYANOINDOL-3-YL)BUTYL-4-(2- -CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE
  申请人：Bathe Andreas

  公开号：US20090023749A1

  公开（公告）日：2009-01-22

  The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.

  本发明涉及1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪盐酸盐的新晶体结构形式，1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪二盐酸盐的晶体结构形式以及非晶态1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪盐酸盐，特别适用于制备用于治疗或预防抑郁症、焦虑症、双相障碍、躁狂、痴呆症、物质相关障碍、性功能障碍、进食障碍、肥胖症、纤维肌痛、睡眠障碍、精神障碍、脑梗塞、紧张等固体药物的制备，以及用于治疗下丘脑功能减退症、继发性闭经、经前期综合征和不良产后泌乳的副作用治疗。
• POLYMORPHIC FORMS OF 1-'4-(5-CYANOINDOL-3-YL) BUTYL-4-(2-CARBAMOYLBENZOFURAN-5-YL)PIPERAZINE HYDROCHLORIDE
  申请人：Bathe Andreas

  公开号：US20100016332A1

  公开（公告）日：2010-01-21

  The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbomyl-benzofuran-5-yl)-piperazine, crystaline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbomyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.

  本发明涉及1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-羧酰基苯并呋喃-5-基)-哌嗪盐酸盐的新晶型、1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-羧酰基苯并呋喃-5-基)-哌嗪双盐酸盐的晶型和非晶态1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-羧酰基苯并呋喃-5-基)-哌嗪盐酸盐。这些晶型特别适用于制备用于治疗或预防抑郁症、焦虑症、双相情感障碍、躁狂症、痴呆、物质相关障碍、性功能障碍、进食障碍、肥胖症、纤维肌痛、睡眠障碍、精神障碍、脑梗塞、紧张情绪以及治疗下丘脑功能减退症、继发性闭经、经前综合症和不期望的产后泌乳的副作用的固体药物。
• POLYMORPHIC FORMS OF 1-'4-(5-CYANOINDOL-3-YL) BUTYL-4-(2-CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE
  申请人：Bathe Andreas

  公开号：US20110183994A1

  公开（公告）日：2011-07-28

  The invention relates to new crystalline Modifications of the hydrochloride of 1-[4-(5-cyanoin-dol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoin-dol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2 -carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.

  本发明涉及1-[4-(5-氰吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪盐酸盐的新晶体形态、1-[4-(5-氰吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪二盐酸盐的晶体形态和无定形1-[4-(5-氰吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪盐酸盐，特别适用于制备用于治疗或预防抑郁症、焦虑症、双相障碍、狂躁症、痴呆症、物质相关障碍、性功能障碍、进食障碍、肥胖症、纤维肌痛、睡眠障碍、精神障碍、脑梗死、紧张等的固体药物，以及用于治疗下丘脑功能减退症、继发性闭经、经前综合征和不良产后泌乳的副作用的治疗。
• POLYMORPHIC FORMS OF 1-'4-(5-CYANOINDOL-3-YL)BUTYL-4-(2-CARBAMOYLBENZOFURAN-5-YL)PIPERAZINE HYDROCHLORIDE
  申请人：BATHE Andreas

  公开号：US20110294824A1

  公开（公告）日：2011-12-01

  The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.

  本发明涉及1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基苯并呋喃-5-基)-哌嗪盐酸盐的新晶体形态、1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基苯并呋喃-5-基)-哌嗪双盐酸盐的晶体形态和非晶态1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基苯并呋喃-5-基)-哌嗪盐酸盐，这些晶体形态特别适用于制备固体药物，用于治疗或预防抑郁障碍、焦虑障碍、躁狂障碍、痴呆症、物质相关障碍、性功能障碍、进食障碍、肥胖症、纤维肌痛、睡眠障碍、精神障碍、脑梗塞、紧张症，用于治疗睾丸功能减退、继发性闭经、经前综合征和不良产后泌乳的副作用疗法。